Ravagalimab - CAS 2050816-56-1

Ravagalimab (ABBV-323) is a CD40 antagonist monoclonal antibody with an EC50 of 3.7 nM. Ravagalimab is being investigated for the treatment of inflammatory diseases such as Crohn’s disease and Sjögren’s syndrome (SS) . Research focuses on evaluating its pharmacological activity, efficacy, and safety in patients with primary Sjögren’s syndrome (pSS), highlighting its role in immune modulation.

TNF

Apoptosis

2050759

0.995

-20°C

Ice Packs

Inhibitory Antibodies